Cite
HARVARD Citation
Ou, S. et al. (2015). Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. Oncologist. pp. 224-226. [Online].